MULTIPLE KERATINOCYTIC CANCERS AFTER INTAKE OF ANTIHYPERTENSIVES (LISINOPRIL/BISOPROLOL/HCT) AND ANTIARRHYTMICS
G Tchernev1, L Ivanov2, V Broshtilova3
11Onkoderma - Clinic for Dermatology, Venereology and Dermatologic Surgery, Sofia; 2Department of Dermatology and Venereology, Medical Institute of Ministry of Interior, Sofia, Bulgaria.
Abstract:
The pathogenesis of cutaneous tumors has been known for decades yet remains largely unexplained or incompletely understood. The reason for this mystery lies in the concepts of photosensitivity and phototoxicity: how do they arise or what actually causes them? Recently published data in the medical literature link certain nitrosamines such as nitrosomorpholine, for example, to gene and phototoxicity in humans. A number of other nitrosamines analogous in action and structure are found as contaminants in about 300 of the most widely distributed pharmaceuticals worldwide: NDEA, NDMA, NMBA and many others. These contaminated drugs include beta blockers/ bisoprolol/, thiazide diuretics/ hydrochlorothiazide/, antiarrhythmics/ propafenone/, ACE inhibitors/ lisinopril/, but also a number of other drugs which are, according to the FDA, found to have contaminants with a certain carcinogenic potency ranging between 1 and 5. The phototoxicity and genotoxicity of these contaminants, attributed to the pathogenesis of skin tumors, still remain a mystery. The problems of the intake of the above-mentioned groups of drugs arise mainly on the basis of the official bulletins of the regulatory bodies, namely that: in practice, the intake of polymedication could in many cases also be considered as regular, permanent, long-term intake of contaminants/carcinogens/mutagens of heterogeneous type, also known as nitrosamines or NDSRIs. Nitrosamines are genome modifiers in humans and cause acquired mutations. Their concomitant administration in the context of standard, but currently not yet officially declared as contaminated polymedication, would be able to block certain tumor suppressor genes (p53) as well as activate RAS oncogenes. Or in practice- daily administration of a particular combination of drugs could activate the cascades of carcinogenesis regulating the genesis of skin cancer. Precisely because of this fact, it should not be surprising to anyone that the concurrent intake of the aforementioned drugs could also be associated with the clinical manifestation of multiple keratinocytic tumors. We describe a consecutive case of a patient who developed 4 keratinocytic tumors: 2 basal cell carcinomas, 1 keratoacanthoma, and 1 squamous cell carcinoma on a background of potentially contaminated polymedication with propafenone, lisinopril, hydrochlorothiazide, and bisoprolol. Recently published innovative international data on the topic are discussed in the context of concepts such as drug-mediated nitrosogenesis, photonitrosо-carcinogenesis and metabolic programming/ reprogramming of the tumor cell.
Insights
Contaminated medications containing nitrosamines may increase skin cancer risk by causing genetic mutations and activating oncogenes. This case study highlights a patient with multiple skin tumors linked to polymedication with drugs containing these harmful contaminants.
Area of Science:
- Oncology
- Dermatology
- Toxicology
Background:
- The precise mechanisms behind cutaneous tumor development, particularly concerning photosensitivity and phototoxicity, remain incompletely understood.
- Recent research implicates nitrosamines, such as nitrosomorpholine, in genotoxicity and phototoxicity in humans.
- Numerous widely used pharmaceuticals contain nitrosamine contaminants (e.g., NDEA, NDMA, NMBA), posing potential carcinogenic risks.
Purpose of the Study:
- To investigate the potential link between nitrosamine-contaminated polymedication and the pathogenesis of cutaneous tumors.
- To explore the role of drug-mediated nitrosogenesis and photonitrosocarcinogenesis in skin cancer development.
- To present a case study illustrating the clinical manifestation of multiple keratinocytic tumors in a patient on contaminated medication.
Main Methods:
- Literature review of recent data on nitrosamines, genotoxicity, and phototoxicity.
- Analysis of FDA data regarding carcinogenic potency of drug contaminants.
- Case study of a patient with multiple keratinocytic tumors and a history of polymedication.
Main Results:
- Nitrosamines found in common drugs (beta blockers, diuretics, antiarrhythmics, ACE inhibitors) are linked to genotoxicity and phototoxicity.
- Polymedication with these drugs constitutes long-term exposure to carcinogens/mutagens, potentially modifying the genome.
- The case patient developed four keratinocytic tumors (2 basal cell carcinomas, 1 keratoacanthoma, 1 squamous cell carcinoma) while on a regimen including propafenone, lisinopril, hydrochlorothiazide, and bisoprolol.
Conclusions:
- Concurrent intake of nitrosamine-contaminated drugs may activate oncogenes (RAS) and block tumor suppressor genes (p53), initiating carcinogenesis.
- Drug-mediated nitrosogenesis and photonitrosocarcinogenesis are plausible mechanisms contributing to skin tumor development.
- This association warrants further investigation into the risks of polymedication with potentially contaminated pharmaceuticals.
More Related Videos
Related Concept Videos
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Cancer Prevention
Some...
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers


![Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F60445.jpg&w=3840&q=50)